Breakthrough Victoria invests in Melbourne-based company ‘with a nose for innovation’
Independent investment company Breakthrough Victoria is investing $800,000 in Diag-Nose.io Medical (DNM), a Melbourne based ...
Zacks.com on MSN15h
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...
Pharmabiz17h
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...
pulmonologyadvisor12h
In COPD Treatment, Tezepelumab Not Linked to Reduced Exacerbations
Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
pulmonologyadvisor15h
COPD Risk Linked to Elevated C-Reactive-Protein-to-Albumin Ratio
Elevated CAR has been associated with adverse outcomes in many conditions, including cancer, sepsis, COVID-19, and cardiovascular diseases. A higher C-reactive protein to albumin ratio (CAR) is ...
Johns Hopkins Medicine23h
Johns Hopkins Medicine
Johns Hopkins Children’s Center ranks #1 in Maryland, and all 11 specialties are ranked nationally on U.S. News & World Report’s Best Children’s Hospitals list. The Johns Hopkins Hospital is one of ...